|
|
|||
|
|||
|
|
|||
|
drug hytrin used for |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
drug hytrin used for Manufacturer: Abbott
Terazosin hydrochloride is a white, crystalline substance, freely soluble inwater and isotonic saline and has a molecular weight of 459.93 drug hytrin used for. HYTRIN capsules(terazosin hydrochloride capsules) for oral ingestion are supplied in four dosagestrengths containing terazosin hydrochloride equivalent to 1 mg, 2 mg, 5 mg,or 10 mg of terazosin drug hytrin used for. Inactive Ingredients: 2 mg capsules: D&C yellow No drug hytrin used for. 10, gelatin, glycerin, methylparaben, mineraloil, polyethylene glycol, povidone, propylparaben, titanium dioxide, and vanillin drug hytrin used for. 5 mg capsules: D&C red No drug hytrin used for. 28, FD&C red No drug hytrin used for. 40, gelatin, glycerin,methylparaben, mineral oil, polyethylene glycol, povidone, propylparaben, titaniumdioxide, and vanillin drug hytrin used for. 10 mg capsules: FD&C blue No drug hytrin used for. 1, gelatin, glycerin, methylparaben, mineraloil, polyethylene glycol, povidone, propylparaben, titanium dioxide, and vanillin drug hytrin used for.
Terazosin has been studied in 1222 men with symptomatic BPH drug hytrin used for. In three placebo-controlledstudies, symptom evaluation and uroflowmetric measurements were performed approximately24 hours following dosing drug hytrin used for. Symptoms were quantified using the Boyarsky Index drug hytrin used for. The questionnaire evaluated both obstructive (hesitancy, intermittency, terminaldribbling, impairment of size and force of stream, sensation of incomplete bladderemptying) and irritative (nocturia, daytime frequency, urgency, dysuria) symptomsby rating each of the 9 symptoms from 0-3, for a total score of 27 points drug hytrin used for. Resultsfrom these studies indicated that terazosin statistically significantly improvedsymptoms and peak urine flow rates over placebo as follows: N Symptom Score
Analysis of the effect of terazosin on individual urinary symptoms demonstratedthat compared to placebo, terazosin significantly improved the symptoms of hesitancy,intermittency, impairment in size and force of urinary stream, sensation ofincomplete emptying, terminal dribbling, daytime frequency and nocturia drug hytrin used for. Global assessments of overall urinary function and symptoms were also performedby investigators who were blinded to patient treatment assignment drug hytrin used for. In studies1 and 3, patients treated with terazosin had a significantly (p </= 0.001)greater overall improvement compared to placebo treated patients drug hytrin used for. In a short term study (Study 1), patients were randomized to either 2, 5 or10 mg of terazosin or placebo drug hytrin used for. Patients randomized to the 10 mg group achieveda statistically significant response in both symptoms and peak flow rate comparedto placebo (Figure 1) drug hytrin used for. + for baseline values see above table * p </= 0.05, compared to placebo group In a long-term, open-label, non-placebo controlled clinical trial, 181 menwere followed for 2 years and 58 of these men were followed for 30 months drug hytrin used for. Theeffect of terazosin on urinary symptom scores and peak flow rates was maintainedthroughout the study duration (Figures 2 and 3): In this long-term trial, both symptom scores and peak urinary flow rates showedstatistically significant improvement suggesting a relaxation of smooth musclecells drug hytrin used for. Although blockade of alpha-1 adrenoceptors also lowers blood pressure in hypertensivepatients with increased peripheral vascular resistance, terazosin treatmentof normotensive men with BPH did not result in a clinically significant bloodpressure lowering effect: Mean Changes in Blood Pressure from
Patients in clinical trials of terazosin were administered once daily (thegreat majority) and twice daily regimens with total doses usually in the rangeof 5-20 mg/day, and had mild (about 77%, diastolic pressure 95-105 mmHg) ormoderate (23%, diastolic pressure 105-115 mmHg) hypertension drug hytrin used for. Because terazosin,like all alpha antagonists, can cause unusually large falls in blood pressureafter the first dose or first few doses, the initial dose was 1 mg in virtuallyall trials, with subsequent titration to a specified fixed dose or titrationto some specified blood pressure end point (usually a supine diastolic pressureof 90 mmHg) drug hytrin used for. Blood pressure responses were measured at the end of the dosing interval (usually24 hours) and effects were shown to persist throughout the interval, with theusual supine responses 5-10 mmHg systolic and 3.5-8 mmHg diastolic greater thanplacebo drug hytrin used for. The responses in the standing position tended to be somewhat larger,by 1-3 mmHg, although this was not true in all studies drug hytrin used for. The magnitude of theblood pressure responses was similar to prazosin and less than hydrochlorothiazide(in a single study of hypertensive patients) drug hytrin used for. In measurements 24 hours afterdosing, heart rate was unchanged drug hytrin used for. Limited measurements of peak response (2-3 hours after dosing) during chronicterazosin administration indicate that it is greater than about twice the trough(24 hour) response, suggesting some attenuation of response at 24 hours, presumablydue to a fall in blood terazosin concentrations at the end of the dose interval drug hytrin used for. This explanation is not established with certainty, however, and is not consistentwith the similarity of blood pressure response to once daily and twice dailydosing and with the absence of an observed dose-response relationship over arange of 5-20 mg, i.e., if blood concentrations had fallen to the point of providingless than full effect at 24 hours, a shorter dosing interval or larger doseshould have led to increased response drug hytrin used for. Further dose response and dose duration studies are being carried out drug hytrin used for. Bloodpressure should be measured at the end of the dose interval; if response isnot satisfactory, patients may be tried on a larger dose or twice daily dosingregimen drug hytrin used for. The latter should also be considered if possibly blood pressure-relatedside effects, such as dizziness, palpitations, or orthostatic complaints, areseen within a few hours after dosing drug hytrin used for. The greater blood pressure effect associated with peak plasma concentrations(first few hours after dosing) appears somewhat more position-dependent (greaterin the erect position) than the effect of terazosin at 24 hours and in the erectposition there is also a 6-10 beat per minute increase in heart rate in thefirst few hours after dosing drug hytrin used for. During the first 3 hours after dosing 12.5% ofpatients had a systolic pressure fall of 30 mmHg or more from supine to standing,or standing systolic pressure below 90 mmHg with a fall of at least 20 mmHg,compared to 4% of a placebo group drug hytrin used for. There was a tendency for patients to gain weight during terazosin therapy drug hytrin used for. In placebo-controlled monotherapy trials, male and female patients receivingterazosin gained a mean of 1.7 and 2.2 pounds respectively, compared to lossesof 0.2 and 1.2 pounds respectively in the placebo group drug hytrin used for. Both differences werestatistically significant drug hytrin used for. During controlled clinical trials, patients receiving terazosin monotherapyhad a small but statistically significant decrease (a 3% fall) compared to placeboin total cholesterol and the combined low-density and very-low-density lipoproteinfractions drug hytrin used for. No significant changes were observed in high-density lipoproteinfraction and triglycerides compared to placebo drug hytrin used for. Analysis of clinical laboratory data following administration of terazosinsuggested the possibility of hemodilution based on decreases in hematocrit,hemoglobin, white blood cells, total protein and albumin drug hytrin used for. Decreases in hematocritand total protein have been observed with alpha-blockade and are attributedto hemodilution drug hytrin used for. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| ddrug hytrin used for drrug hytrin used for druug hytrin used for drugg hytrin used for drug hytrin used for drug hhytrin used for drug hyytrin used for drug hyttrin used for drug hytrrin used for drug hytriin used for drug hytrinn used for drug hytrin used for drug hytrin uused for drug hytrin ussed for drug hytrin useed for drug hytrin usedd for drug hytrin used for drug hytrin used ffor drug hytrin used foor drug hytrin used forr rug hytrin used for dug hytrin used for drg hytrin used for dru hytrin used for drughytrin used for drug ytrin used for drug htrin used for drug hyrin used for drug hytin used for drug hytrn used for drug hytri used for drug hytrinused for drug hytrin sed for drug hytrin ued for drug hytrin usd for drug hytrin use for drug hytrin usedfor drug hytrin used or drug hytrin used fr drug hytrin used fo d rug hytrin used for dr ug hytrin used for dru g hytrin used for drug hytrin used for drug hytrin used for drug h ytrin used for drug hy trin used for drug hyt rin used for drug hytr in used for drug hytri n used for drug hytrin used for drug hytrin used for drug hytrin u sed for drug hytrin us ed for drug hytrin use d for drug hytrin used for drug hytrin used for drug hytrin used f or drug hytrin used fo r drug hytrin used for rdug hytrin used for durg hytrin used for drgu hytrin used for dru ghytrin used for drugh ytrin used for drug yhtrin used for drug htyrin used for drug hyrtin used for drug hytirn used for drug hytrni used for drug hytri nused for drug hytrinu sed for drug hytrin sued for drug hytrin uesd for drug hytrin usde for drug hytrin use dfor drug hytrin usedf or drug hytrin used ofr drug hytrin used fro adrug hytrin used for thedrug hytrin used for drug hytrin used for | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
